EIF2A

Eukaryotic translation initiation factor 2A · Q9BY44 · EIF2A on Sugi Atlas →

0 patent compounds predicted against EIF2A, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EIF2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. PHASE1/PHASE2RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Quantification of GADD34 Expression in RA nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey nanCOMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
GADD34 and Type I IFN Response Genes in SLE nanCOMPLETED
The Effects of Whey vs. Collagen on MPS nanCOMPLETED
Effect of Protein on Endoplasmic Reticulum Stress nanNOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Mitoquines in COPD nanUNKNOWN
Efficacy and Safety of Administration of High Levels of Protein to Critically Ill Patients. nanACTIVE_NOT_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EIF2A binder may also engage these)

ProteinNameSimilarity
Q8BJW6 1.000 Q8BJW6 →
Q5ZKC1 1.000 Q5ZKC1 →
Q7ZY11 1.000 Q7ZY11 →
Q4QRJ7 1.000 Q4QRJ7 →
O74965 0.999 O74965 →
B4KNN9 0.997 B4KNN9 →
B0W562 0.995 B0W562 →
Q0CN46 0.995 Q0CN46 →
Q19052 0.995 Q19052 →
Q5BGH1 0.995 Q5BGH1 →
Q9C5Z1 0.994 Q9C5Z1 →
Q9VNX8 0.994 Q9VNX8 →
Q7S464 0.994 Q7S464 →
Q1HDZ5 0.994 Q1HDZ5 →
A1CS92 0.994 A1CS92 →
B0XRG7 0.993 B0XRG7 →
A3LY29 0.993 A3LY29 →
Q1DI97 0.993 Q1DI97 →
A2Q908 0.993 A2Q908 →
B4J6D5 0.992 B4J6D5 →
A6SFQ6 0.992 A6SFQ6 →
B4QB88 0.992 B4QB88 →
Q4WKL7 0.992 Q4WKL7 →
B4LM71 0.992 B4LM71 →
B3NMI5 0.992 B3NMI5 →
B4HMV9 0.992 B4HMV9 →
Q0E940 0.992 Q0E940 →
Q6CY34 0.992 Q6CY34 →
Q0IEY3 0.991 Q0IEY3 →
B3ME25 0.991 B3ME25 →